Be Biopharma to use MaxCyte's Flow Electroporation technology and ExPERT platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Investors considering a purchase of MaxCyte Inc (MXCT) shares, but cautious about paying the going market price of 4.26/share, might benefit from considering selling puts among the alternative...
MaxCyte (NASDAQ:MXCT Get Free Report)s stock had its outperform rating reiterated by investment analysts at William Blair in a report released on Wednesday, RTT News...
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
